Immunomedics, Inc. IMMU today announced that a single dose of clivatuzumab tetraxetan labeled with the potent therapeutic radioisotope, yttrium-90, produced transient partial responses in some patients with advanced pancreatic cancer and the treatment was well tolerated with manageable hematological toxicity at the maximum tolerated 90Y dose.
Results from this Phase I study were published online in Clinical Cancer Research by S.A. Gulec, S.J. Cohen, K.L. Pennington, L.S. Zuckier, R.J. Hauke, H. Horne, W.A. Wegener, N. Teoh, D.V. Gold, R.M. Sharkey and D.M. Goldenberg in an article entitled "Treatment of advanced pancreatic carcinoma with 90Y-clivatuzumab tetraxetan: A Phase I single-dose escalation trial."
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in